Ertapenem: profile and news
FDA Approves New Indication for INVANZ(R) (ertapenem) for the ... Nov 14, 2005
...announced today that the US Food and Drug Administration (FDA) has approved INVANZ(R) (ertapenem), a once-daily injectable antibiotic, for the treatment of ... - Business Wire (press release),
FDA Approvals: Exjade, Oncaspar, Invanz Nov 17, 2005
...in patients aged two years and older; an intravenous route of administration for pegaspargase injection; and a new indication for ertapenem injection, allowing ... - Medscape (subscription)
Take care of your feet Dec 4, 2005
There are many active components available in the market that help these patients, such as Ertapenem, to treat skin infections and others. DJ Staff. - Daily Journal,
Once-Daily IV Antibiotic Effective for Diabetic Foot Infections Nov 10, 2005
11 - Invanz (ertapenem) is as effective as Zosyn (piperacillin/tazobactam) for diabetic foot infections but has the convenience of once-daily dosing, according ... - MedPage Today,
Merck Announces New Unisured Discount Program Targeted to More ... Oct 7, 2005
CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, and EMEND(R) (aprepitant), INVANZ(R) (ertapenem for injection ... - Hispanic PR Wire (press release),
ALLERGIC CROSS-SENSITIVITY BETWEEN PENICILLIN AND CARBAPENEM ... Aug 31, 2005
...articles. Key search terms were carbapenem, imipenem, meropenem, ertapenem, drug hypersensitivity, and penicillin allergy. STUDY ... - The Journal of Pharmacy Technology
Merck Announces New Unisured Discount Program Targeted to More ... Apr 19, 2005
CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, and EMEND(R) (aprepitant), INVANZ(R) (ertapenem for injection ... - Hispanic PR Wire
Governor Tom Vilsack Supports New Merck Uninsured Discount Program ... Apr 20, 2005
...including CANCIDAS(R) (caspofungin acetate) for Injection, CRIXIVAN(R) (indinavir sulfate) Capsules, EMEND(R) (aprepitant), INVANZ(R) (ertapenem for injection ... - PR Newswire
